<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918358</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VRCL005</org_study_id>
    <nct_id>NCT01918358</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg</brief_title>
  <official_title>A Randomized, Open-label, Single Dose Crossover Study to Compare the Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and pharmacokinetics between ROVATITAN tab. 160/20 mg (ROVATITAN tab
      160/20mg-1, ROVATITAN tab. 160/20mg-2) and coadministration of Diovan® (Valsartan) 160 mg and
      Crestor® (Rosuvastatin) 20 mg in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of valsartan and rosuvastatin</measure>
    <time_frame>0h(pre-dosing), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 12h, 24h, 48h for each period (total 16 times)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC last of valsartan and rosuvastatin</measure>
    <time_frame>0h(pre-dosing), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 12h, 24h, 48h for each period (total 16 times)</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>-28~-2d, 1d, 2d, 3d, 8d, 9d, 10d, 15d, 16d, 17d, 21 ± 2d</time_frame>
    <description>The severity of adverse events and their relationship with the investigational products are schematized by treatment group. Descriptive statistics are calculated for the frequency, percentage, 12-lead ECG and clinical laboratory tests results of the subjects who have adverse events and the results of each item are reviewed.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 160mg placebo + Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)</intervention_name>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-1</arm_group_label>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-2</arm_group_label>
    <arm_group_label>Valsartan 160mg placebo + Rosuvastatin 20mg</arm_group_label>
    <other_name>Rovatitan tab</other_name>
    <other_name>Diovan</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)</intervention_name>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-1</arm_group_label>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-2</arm_group_label>
    <arm_group_label>Valsartan 160mg placebo + Rosuvastatin 20mg</arm_group_label>
    <other_name>Rovatitan tab</other_name>
    <other_name>Diovan</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)</intervention_name>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-1</arm_group_label>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-2</arm_group_label>
    <arm_group_label>Valsartan 160mg placebo + Rosuvastatin 20mg</arm_group_label>
    <other_name>Rovatitan tab</other_name>
    <other_name>Diovan</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )</intervention_name>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-1</arm_group_label>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-2</arm_group_label>
    <arm_group_label>Valsartan 160mg placebo + Rosuvastatin 20mg</arm_group_label>
    <other_name>Rovatitan tab</other_name>
    <other_name>Diovan</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )</intervention_name>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-1</arm_group_label>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-2</arm_group_label>
    <arm_group_label>Valsartan 160mg placebo + Rosuvastatin 20mg</arm_group_label>
    <other_name>Rovatitan tab</other_name>
    <other_name>Diovan</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)</intervention_name>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-1</arm_group_label>
    <arm_group_label>Fixed-dose combination VR 160/20 mg-2</arm_group_label>
    <arm_group_label>Valsartan 160mg placebo + Rosuvastatin 20mg</arm_group_label>
    <other_name>Rovatitan tab</other_name>
    <other_name>Diovan</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male aged 20~45 years at screening

          2. 19 kg/m2 ≤ BMI ≤27 kg/m2 at screening

          3. Subject who is able to communicate with investigators and understand the nature of the
             clinical study and is willing and able to provide a written informed consent form

        Exclusion Criteria:

          1. Subject with current or previous clinically significant diseases in liver, renal,
             neurologic, pulmonary, gastrointestinal, endocrine, hematologic, oncologic,
             cardiovascular, psychological, and musculoskeletal system

          2. Patient with renal defects (Calculated GFR &lt; 60 ml/min based on serum creatinine level
             )

          3. Subject who can not satisfy the following criteria for sitting blood pressure at
             screening test 90 ≤SBP &lt;140 (mmHg) 60 ≤ DBP &lt;90 (mmHg)

          4. Subject who can not satisfy the following criteria at screening 1) AST and ALT ≤ 1.5x
             ULN 2) Serum total bilirubin ≤ 1.5x ULN 3) CK (Creatinine kinase) ≤ 2x ULN

          5. Subject with a medical history of gastrointestinal diseases (e.g., Crohn's disease,
             ulcer) or a surgery (for appendicitis and hernia repair are allowed) that might affect
             the investigational product absorption

          6. Subject with hypersensitivity to the drugs containing components of valsartan and
             rosuvastatin or other drugs (aspirin, antibiotics) or a previous clinically
             significant history of hypersensitivity

          7. Subject with a previous history of drug overdose or a positive to the drugs
             (Barbiturate, Benzodiazepine, Methamphetamine, Cannabinoids, Cocaine, Opiate) in urine
             drug screening test

          8. Subject who has taken any prescribed medicines or oriental medicines within two weeks
             before the first investigational product administration, or who has taken any
             over-the-counter drugs within one week before the first investigational product
             administration (If the subject is eligible for all other criteria, he or she may
             participate in the clinical study based on investigator's discretion.)

          9. Subject who has taken other investigational products within 60 days before the first
             investigational product administration

         10. Subject who donated whole blood within 60 days or donated apheresis blood within 30
             days or received a transfusion within 30 days before the first investigational product
             administaration.

         11. Subject who has taken the drugs that induce or inhibit drug-metabolizing enzymes such
             as barbiturates within 30 days before the first investigational product administration

         12. Subject with a daily intake of drinks containing caffeine (coffee, tea, coke) or
             grapefruit juice &gt; average of 4 cups / day (800 mL) or a subject who can not
             discontinue such drinks during the clinical study period(from screening to post-study
             visit)

         13. Subject with a mean weekly drinking amount of &gt; 140g or a subject who can not stop
             drinking until outpatient visit after the investigational product administration,
             including the hospitalization in each period.

         14. Subject with a mean daily smoking amount of &gt; 10 cigarettes or a subject who can not
             stop smoking during the hospitalization

         15. Subject positive result in serology tests (hepatitis B, hepatitis C, HIV)

         16. Subject with genetic muscle disease, or familial history of muscle disease, or medical
             history of drug-derived muscle disorder

         17. Subject who is considered not to be eligible at investigator's discretion.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

